

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro- oesophageal junction cancer after anti-HER2 treatment (terminated appraisal)

Technology appraisal guidance

Published: 6 April 2023

www.nice.org.uk/guidance/ta879

Contents

Advice.....	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after a previous anti-HER2-based regimen in adults. This is because Daiichi Sankyo UK has confirmed that it does not intend to make an evidence submission for the appraisal at this time. Daiichi Sankyo UK considers that collecting further evidence from the DESTINY-Gastric clinical trials will allow them to provide a more comprehensive evidence submission for this appraisal.

Information

If NHS organisations wish to consider trastuzumab deruxtecan for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-5131-4

Accreditation

